1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Enorama Pharma AB

Enorama Pharma AB

SSTO:ERMA
0.87
SEK
-0.19
(-17.55%)
-0.80EPS
20.14MMarket Cap
Enorama Pharma AB
STO:ERMA
(Nasdaq Stockholm)

Recent

price

0.87

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
- -
- -
0.26
0.8
1.14
0.23
1.16
0.48
0.03
0.26
0.04
0.02
Revenue per Share
- -
-0.14
-1.51
-1.47
-2.49
-3.58
-2.47
-2.92
-2.92
-1.09
-0.72
-1.01
-0.8
Basic EPS, GAAP
-0.23
-0.33
-1.94
-1.75
-3.13
-4.62
-2.82
-3.36
-2.29
-1.01
-0.59
-0.79
-0.72
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.46
1.14
1.58
1.21
2.6
1.05
0.24
2.25
2.72
0.39
0.13
-0.31
-0.68
Book Value per Share
-0.18
0.15
-0.1
-0.99
-0.47
-2.3
-3.21
-0.52
0.7
-0.02
0.12
-0.32
-0.68
Tangible Book Value per Share
5
5
5
6
7
7
10
10
14
41
60
75
75
Basic Weighted Avg Shares
- -
- -
- -
2
5
8
2
11
7
1
16
3
1
Sales/Revenue/Turnover
- -
- -
- -
-502.59
-294.76
-300.56
-1,072.27
-245.81
-612.9
-3,079.82
-301.86
-2,267.91
-3,687.43
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
4
4
20
- -
- -
Depreciation Expense
- -
-1
-8
-9
-16
-24
-23
-28
-42
-45
-44
-75
-60
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-556.67
-310.87
-312.69
-1,093.01
-251.38
-613.85
-3,285.2
-277.82
-2,743.3
-4,121.55
Profit Margin (%)
-1
-1
3
-3
4
8
-6
11
-1
3
7
-24
-26
Working Capital
- -
1
3
3
- -
- -
4
2
- -
- -
- -
- -
- -
LT Debt
3
7
9
7
17
7
2
21
32
20
8
-23
-50
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-14.29
-100.44
-106.51
-134.04
-196.7
-523.81
-239.87
-158.97
-174.74
-320.44
- -
- -
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
75
Market Capitalization
142
26
20

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8
23
7
Cash, Cash Equivalents & STI
3
18
2
Accounts Receivable, Net
2
1
1
Inventories
2
2
2
Total Current Liabilities
32
35
33
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
66.91%
130.14%
-400.54%
Free Cash Flow
80.51%
20.01%
65.99%
Net Income, GAAP
138.22%
29.13%
71.53%
Sales/Revenue/Turnover
- -
254.92%
-82.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
6
7
3
16
2025
- -
1
- -
2
3
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.19
-0.14
-0.12
-0.36
-0.72
2025
-0.37
-0.28
-0.18
-0.28
-1.01
2026
-0.17
-0.18
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Enorama Pharma AB (publ) operates as a Swedish pharmaceutical firm, dedicated to the creation, production, and commercialization of consumer-friendly oral nicotine products. The company's portfolio includes tobacco-free nicotine pouches under its NIC-S® brand, alongside medicinal chewing gums developed through its ChewMed® technology platform for applications such as nicotine replacement therapy and other drug delivery needs. Based in Malmö, Sweden, with a presence in the USA, the firm is strategically focusing on the expansion of its nicotine pouch business and is exploring the divestment of its NRT chewing gum division. Nasdaq Stockholm has recently issued the company observation status due to its financial position.